Turkey has moved from a holiday reputation built on sun, sea and sand to a genuine force in medical tourism, and the shift was deliberate rather than accidental. Newsweek reported on the transformation through the story of Anadolu Medical Center Hospital and its Gebze facility, which began operating in 2005. Aslı Akyavaş Pamuk, Anadolu’s Director of International Services, recalled that health tourism in Turkey then meant mostly elective work, hair transplants, thermal spring therapies, and some dental or in vitro fertilisation treatment. The hospital wanted something more ambitious. It set out to build a centre for excellence in oncology and cancer treatment for Turkey and its neighbouring countries, a target well above the market of the day.
Anadolu and Turkey’s climb up the hospital rankings
Nearly two decades on, that ambition has been recognised. Anadolu was listed among the top 250 in Newsweek and Statista’s World’s Best Hospitals 2026 and placed third nationally, Newsweek reported. The recognition carries extra weight because 2024 was the first year Turkey appeared in the ranking at all, as the list widened to cover more of the world’s leading healthcare destinations. Akyavaş Pamuk framed the listing as a reflection of a long commitment to quality, safety and international standards of care.
The numbers behind the reputation are just as striking. The Turkish Statistical Institute reported a surge of more than 168 per cent in medical tourism visitor numbers between 2021 and 2023, a rate of growth that points to a real shift in where patients are willing to travel. Acıbadem Healthcare Group, ranked the fourth-best hospital in Turkey, expects the country’s role to expand further over the coming decade. Deniz Şentop, Acıbadem’s Director of International Marketing and Communications, put the appeal down to a mix of highly trained physicians, modern hospital infrastructure, advanced medical technologies, and a location within easy reach of Europe, Asia and the Middle East.
Accreditation and the virtuous cycle of investment
Acıbadem started treating international patients in the early 2000s, drawn in at first by demand it had not gone looking for. That early flow of patients, and the foreign capital that came with them, funded a system-wide upgrade. The money paid for new medical technology, for specialist physicians and staff, for expanded research programmes, and for better clinical facilities. It also paid for accreditation. Turkey now holds one of the highest counts of internationally accredited hospitals anywhere, with more than 35 facilities carrying the standard, and chasing those credentials forces hospitals to tighten clinical protocols and hold to strict patient safety standards.
“International patients come with higher expectations,” Akyavaş Pamuk said, and meeting them means raising quality credentials and aligning with international standards. The same pressure pushed Turkish hospitals toward speed as well as quality. At Anadolu that has meant shorter waits for appointments and procedures, simpler admission and discharge, and workflows that let a patient complete a full course of treatment under one roof. Şentop described the result as a loop, in which the ability to invest in the latest technology attracts more complex international cases, which in turn deepen expertise and reputation. That loop is the trickle-down destination economy working as intended, and it is the strongest argument for treating inbound patients as an investment in domestic capacity rather than a side business.
Where Turkey’s international patients come from
The revenue has funded specialisation. Turkish hospitals have built centres for oncology, organ transplantation, robotic surgery, and advanced radiotherapy, Newsweek reported. International patients are a smaller share of Acıbadem’s total volume, yet Şentop argued that the economic value they generate ends up benefiting every patient, domestic and international alike. Anadolu shows the same pattern, with Turkish citizens making up roughly 90 per cent of all patients and about 70 per cent of its cancer patients. The domestic mission still comes first, even as the international business grows. The Turkish Statistical Institute’s headline figure, a surge of more than 168 per cent in medical tourism visitor numbers between 2021 and 2023, is the clearest measure of how fast that international business has grown.
The map of where those international patients come from is instructive. The largest flows to both Acıbadem and Anadolu have historically come from the Balkans, Eastern Europe, the Middle East and North Africa. Bulgaria is consistently the leading country for Anadolu, which also draws patients from Romania, Georgia, Uzbekistan, Azerbaijan, Kazakhstan and Russia, and treats around 10,000 international patients a year. A single dominant source market is a concentration risk, and the recent rise in demand from Western Europe, the United Kingdom and North America is the useful correction. As American healthcare costs keep climbing, Akyavaş Pamuk expects more United States patients to travel to Turkey for value and advanced care.
Why patients choose Turkey beyond cost
Cost is the obvious explanation, and it is the wrong one to lead with. Şentop was clear that price is rarely the main reason foreign patients choose the country. The pull, in his account, is medical expertise, advanced technology, and the chance to be treated without the long waits common in other systems, where a procedure can be months or even years away. That maps onto the five reasons patients cross borders for care, that treatment abroad is better, is the best available, is cheaper, is faster, or is simply not on offer at home. Turkey is competing mostly on better and faster, not on cheaper, and that is the more durable position to hold.
The foundation under all of it is trust, built slowly. Anadolu ran for years without much of a marketing budget, on the principle that a happy patient refers another patient, Akyavaş Pamuk recounted. She described a cultural shift from physician-oriented care to patient-centred care that took two decades to complete and was, in her telling, a hard road. That is the part rivals cannot buy quickly. A healthcare destination is built from the inside out, and the dull machinery of accreditation, workforce and safety has to run before the brand can be sold. Turkey’s rise looks fast from the outside, but it rests on twenty years of that unglamorous work, and the geopolitical exposure of a hub wedged between Europe, Asia and the Middle East is the standing risk that the next decade will test.
